Allogene Therapeutics, Inc. reported $6.8M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $6.8M (to Q2 2026). Net income: −$165M, trailing twelve months to Q2 2026. Free cash flow: −$103M, trailing twelve months to Q2 2026. Operating margin: −4811%, trailing twelve months to Q2 2026.

ALLOAllogene Therapeutics, Inc.

Healthcare

$1.40+3.7% 1Y

$1.40

$1.0552 weeks$3.06

ALLO as reported

Allogene Therapeutics, Inc. reported $6.8M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

$6.8M

Revenue, trailing twelve months · to Q2 2026 · every figure below is as filed, with no scoring applied

Net income: −$165M
Net income · −30% year on year · trailing twelve months to Q2 2026
Free cash flow: −$103M
Free cash flow · −41% year on year · trailing twelve months to Q2 2026
Operating margin: −4811%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ALLO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$6.8M	n/a	Q2 2026
Net income	−$165M	−30%	Q2 2026
EPS	−$0.67	−40%	Q2 2026
Operating margin	−4811%	n/a	Q2 2026
Net margin	−4426%	n/a	Q2 2026
ROE	−58%	n/a	Q2 2026
ROA	−42%	n/a	Q2 2026
Free cash flow	−$103M	−41%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.